Find Reports
Select Report Type
Reimbursement Review
Displaying 326 - 350 of 1422
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| Avelumab (Bavencio) for Urothe... | Bavencio | Avelumab | Urothelial Carcinoma (UC) | Reimburse with clinical criteria and/or conditions | Complete | PC0225-000 | |||
| von Willebrand Factor [recombi... | Vonvendi | von Willebrand Factor [recombinant] | von Willebrand disease, adults, treatment and perioperative management | Reimburse with clinical criteria and/or conditions | Complete | ST0639-000 | |||
| Nivolumab-Ipilimumab for Non-S... | Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | NSCLC | Reimburse with clinical criteria and/or conditions | Complete | PC0218-000 | |||
| ofatumumab | Kesimpta | ofatumumab | Multiple Sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete | SR0657-000 | |||
| apomorphine hydrochloride | Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | SR0650-000 | |||
| nintedanib | Ofev | nintedanib | chronic fibrosing interstitial lung diseases | Reimburse with clinical criteria and/or conditions | Complete | SR0654-000 | |||
| Adult B-Cell Precursor Acute L... | B-Cell Precursor Acute Lymphoblastic Leukemia | Complete | PH0002-000 | ||||||
| Levetiracetam | pdp-levETIRAcetam | Levetiracetam | Epilepsy | Reimburse with clinical criteria and/or conditions | Complete | SR0653-000 | |||
| Entrectinib (Rozlytrek) for RO... | Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete | PC0206-000 | |||
| vedolizumab | Entyvio | vedolizumab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Complete | SR0647-000 | |||
| Acalabrutinib (Calquence) for ... | Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Reimburse with clinical criteria and/or conditions | Complete | PC0210-000 | |||
| Glasdegib (Daurismo) for acute... | Daurismo | Glasdegib | Acute Myeloid Leukemia (AML) | Do not reimburse | Complete | PC0207-000 | |||
| dapagliflozin | Forxiga | dapagliflozin | Heart failure with reduced ejection fraction | Reimburse with clinical criteria and/or conditions | Complete | SR0642-000 | |||
| Pembrolizumab (Keytruda) for H... | Keytruda | Pembrolizumab | head and neck squamous cell carcinoma (HNSCC) | Reimburse with clinical criteria and/or conditions | Complete | PC0216-000 | |||
| emicizumab | Hemlibra | emicizumab | Bleeding prevention, hemophilia A | Reimburse with clinical criteria and/or conditions | Complete | ST0651-000 | |||
| esketamine hydrochloride | Spravato | esketamine hydrochloride | Major depressive disorder (MDD), adults | Do not reimburse | Complete | SR0621-000 | |||
| Brentuximab Vedotin (Adcetris)... | Adcetris | Brentuximab Vedotin | Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) | Reimburse with clinical criteria and/or conditions | Complete | PC0214-000 | |||
| Brentuximab Vedotin (Adcetris)... | Adcetris | Brentuximab Vedotin | Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) | Reimburse with clinical criteria and/or conditions | Complete | PC0213-000 | |||
| indacaterol /mometasone furoat... | Atectura Breezhaler | indacaterol /mometasone furoate | Asthma maintenance (adults, children 12 or older) | Reimburse with clinical criteria and/or conditions | Complete | SR0646-000 | |||
| Indacaterol glycopyrronium m... | Enerzair Breezhaler | indacaterol glycopyrronium mometasone furoate | Asthma maintenance, adults | Reimburse with clinical criteria and/or conditions | Complete | SR0645-000 | |||
| Acalabrutinib (Calquence) for ... | Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | PC0211-000 | |||
| Tecentriq & Avastin for He... | Tecentriq & Avastin | Atezolizumab & Bevacizumab | Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | PC0217-000 | |||
| Venetoclax (Venclexta) in comb... | Venclexta | Venetoclax Obinutuzumab | Obinutuzumab for CLL | Reimburse with clinical criteria and/or conditions | Complete | PC0212-000 | |||
| voretigene neparvovec | Luxturna | voretigene neparvovec | Vision loss, inherited retinal dystrophy | Reimburse with clinical criteria and/or conditions | Complete | SG0643-000 | |||
| Blincyto for MRD-positive B-ce... | Blincyto | Blinatumomab | MRD+ ALL Resubmission | Reimburse with clinical criteria and/or conditions | Complete | PC0204-000 |
Health Technology Review
Displaying 326 - 350 of 600
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 326 - 350 of 2132
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| tralokinumab | Reimbursement Review | Complete | SR0787-000 | ||||
| cemiplimab | Reimbursement Review | Complete | PC0331-000 | ||||
| Review of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update | Health Technology Review | Rapid Review | Completed | RC1541-000 | |||
| The Paige Prostate Suite: Assistive Artificial Intelligence for Prostate Cancer Diagnosis | Our Horizon Scan explores the Paige Prostate Suite, a set of artificial intelligence (AI) applications that works alongside pathologists reviewing prostate biopsy samples. The system requires pathology slides to be digitized for the suite to be able to highlight areas of suspicion for review. | Horizon Scan | Emerging Health Technologies | Completed | EH0123-000 | ||
| teclistamab | Reimbursement Review | Complete | PC0332-000 | ||||
| Thrombopoietin Receptor Agonists as Second-Line Treatment in Children With Ongoing Immune Thrombocytopenia | Health Technology Review | Technology Review | Completed | HC0033-000 | |||
| Methoxyflurane Inhalation as an Analgesic for Minor Gynecological, Ambulatory, or Emergency Procedures | Health Technology Review | Rapid Review | Completed | RC1545-000 | |||
| Retesting Intervals for Tryptase | Health Technology Review | Rapid Review | Completed | RC1546-000 | |||
| Drug Shortages and Patient Harms | The objective of our report is to summarize the evidence on patient outcomes associated with supply chain disruptions of pharmaceuticals and vaccines. | Health Technology Review | Technology Review | Completed | HC0072-000 | ||
| Safety of Ozempic for Type II Diabetes | Health Technology Review | Observational Study | Completed | OS0005-000 | |||
| infliximab | Reimbursement Review | Complete | SR0816-001 | ||||
| infliximab | Reimbursement Review | Complete | SR0816-000 | ||||
| An Inventory of Rare Disease Registries in the Canadian Landscape | Health Technology Review | Environmental Scan | Completed | CP0033-000 | |||
| Pharmaceutical Reviews Update — Issue 50 | Reimbursement Review | Pharmaceutical Review Update | |||||
| Alternate level of care (ALC) | Health Technology Review | Optimal Use | Active | OP0557-000 | |||
| Review of Guidelines on Clonidine for Various Indications | Health Technology Review | Rapid Review | Completed | RC1543-000 | |||
| Efficacy and Safety of Treatment Options for Uncomplicated Gonococcal Infections | Health Technology Review | Rapid Review with Expert Input | Completed | RD0070-000 | |||
| cannabidiol | Reimbursement Review | Complete | SR0800-000 | ||||
| The Canadian Medical Imaging Inventory: 2022–2023 |
Canadian Medical Imaging Inventory 2022– 2023: CTCanadian Medical Imaging Inventory 2022– 2023: MRICanadian Medical Imaging Inventory 2022– 2023: PET-CT and PET-MRICanadian Medical Imaging Inventory 2022–2023: SPECT and SPECT-CTCanadian Medical Imaging Inventory 2022–2023: Provincial and Territorial Overvi…Canadian Medical Imaging Inventory 2022–2023: The Medical Imaging TeamCanadian Medical Imaging Inventory 2022– 2023: MethodsThe Canadian Medical Imaging Inventory 2022–2023 - Evidence Preview |
Health Technology Review | Technology Review | Completed | HC0024-000 | ||
| Evidence Review of Treatment Options for Uncomplicated Gonococcal Infections | Health Technology Review | Technology Review | Completed | RE0046-000 | |||
| Re-Treatment With Immune Checkpoint Inhibitors | Health Technology Review | Summary with Critical Appraisal | Completed | RC1544-000 | |||
| Strategies to Reduce Alternate Level of Care | We analyzed CIHI data related to ALC and average length of ALC in older adults. We also conducted an environmental scan of the academic and grey literature to identify strategies to address ALC in older adults in Canada and strategies that have been effective in reducing ALC in older adults. | Horizon Scan | Completed | EH0126-000 | |||
| Large B cell lymphoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0048-000 | |||
| Cutaneous Melanoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0049-000 | |||
| Multiple Myeloma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0047-000 |